Welcome to the e-CCO Library!

DOP014: Impact of genetic variation on gene and protein expression in Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Hart*, K. Hayden, E. Wadman, S. Bhagat, D. Jacobstein, C. Brodmerkel, J. Friedman, K. Li

Created: Thursday, 21 February 2019, 9:14 AM
DOP014: Nutritional optimisation of presurgical Crohns disease patients with enteral nutrition significantly decreases length of stay and need for a stoma
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. V. Patel*1, A. M. Sandall2, D. V. O’Hanlon3, A. A. Darakhshan4, A. B. Williams4, S. H. Anderson1, P. M. Irving1, M. C. Lomer5, J. D. Sanderson1

Created: Friday, 22 February 2019, 9:49 AM
DOP014: Transmural healing is better than mucosal healing in Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Raimundo Fernandes S.*1, Vale Rodrigues R.2, Bernardo S.1, Cortez Pinto J.2, Rosa I.2, Correia L.1, Moura Santos P.3, Rita Gonçalves A.3, Valente A.3, Baldaia C.3, Pereira da Silva J.2, Dias Pereira A.2, Velosa J.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP015: Dysregulation of cell-type-specific long ncRNA in the ileum of treatment naïve early onset Crohn disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

Y. Haberman1,2*, M. BenShoshan1, A. Di Segni1, P.J. Dexheimer3, T. Braun1, B. Weiss1, C. Avivi1, I. Barshack1, Y. Anikster1, B. Aronow3, J.S. Hyams4, S. Kugathasan5, L.A. Denson3, The Crohn's & Colitis Foundation (CCF)-sponsored RISK study

Created: Thursday, 21 February 2019, 9:14 AM
DOP015: International differences in gastroenterologists' perspective on stopping therapy for patients with Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Siegel C.A.*1, Thompson K.D.1, Walls D.2, Gollins J.3, Colombel J.-F.4, Louis E.5 on behalf of the BIOCYCLE Group5

Created: Wednesday, 20 February 2019, 10:36 AM
DOP015: Myenteric plexitis is a risk factor for endoscopic and clinical postoperative recurrence after ileocolonic resection in Crohns disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Decousus1, A.-L. Boucher2, J. Joubert1, M. Goutte2, 3, F. Goutorbe2, A. Dubois4, B. Pereira5, P. Dechelotte1, G. Bommelaer2, 3, A. Buisson*2, 3

Created: Friday, 22 February 2019, 9:49 AM
DOP016: Long-term safety of in utero exposure to anti-tumor necrosis factor for the treatment of inflammatory bowel diseases: results from the multicenter European TEDDY study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Chaparro M.*1, Verreth A.2, Lobaton T.3, Gravito-Soares E.4, Julsgaard M.5, Savarino E.6, Magro F.7, Avni Biron I.8, Lόpez-Serrano P.9, Casanova M.1, Gompertz M.10, Vitor S.11, Arroyo M.12, Pugliese D.13, Zabana Y.14, Vicente R.15, Aguas M.16, Bar-Gil Shitrit A.17, Gutierrez A.18, Doherty G.19, Fernández-Salazar L.20, Martinez Cadilla J.21, Huguet J.22, O'Toole A.23, Stasi E.24, Manceñido Marcos N.25, Villoria A.26, Karmiris K.27, Rahier J.28, Rodriguez C.29, Diz-Lois Palomares M.30, Fiorino G.31, Benítez J.32, Principi M.33, Naftali T.34, Taxonera C.35, Mantzaris G.36, Sebkova L.37, Iade B.38, Lissner D.39, Ferrer Bradley I.40, Lόpez-San Román A.41, Marín-Jiménez I.42, Merino O.43, Sierra M.44, Van Domselaar M.45, Caprioli F.46, Guerra I.47, Peixe P.48, Piqueras M.49, Rodríguez-Lago I.50, Ber Y.51, Van Hoeve K.2, Torres P.3, Gravito-Soares E.4, Rudbeck-Thomsen D.5, Bartolo O.6, Peixoto A.7, Martín G.8, Pérez J.1, Garre A.1, Donday M.G.1, Martín de Carpi J.52, Gisbert J.P.1 Gastroenterology Units, on behalf of the TEDDY Study Group Investigators

Created: Wednesday, 20 February 2019, 10:36 AM
DOP016: Metagenomic analysis of intestinal mucosa revealed an IBD-specific shift in the eukaryotic gut virome composition at early stages of gut inflammation
Year: 2018
Source: ECCO '18 Vienna
Authors:

F. Ungaro1*, L. Massimino2, S. D'Alessio1, S. Danese1

Created: Thursday, 21 February 2019, 9:14 AM
DOP016: Postoperative clinical recurrence is not different in Crohns disease patients classified as i2 on the Rutgeerts score with lesions confined to the ileocolonic anastomosis than in those with lesions of the neoterminal ileum
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. Bayart*1, N. Duveau1, M. Nachury1, P. Zerbib1, R. Gerard1, J. Branche1, V. Maunoury1, A. Boruchowicz2, M. Boualit2, J.-E. Laberenne3, O. Manolache3, G. Pineton de Chambrun4, B. Pariente1

Created: Friday, 22 February 2019, 9:49 AM
DOP017: Colectomy-free survival is independent of initial infliximab dosing strategy in hospitalised ulcerative colitis patients
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Shah*, S. Naymagon, B. Sands, B. Cohen, M. Dubinsky

Created: Friday, 22 February 2019, 9:49 AM
DOP017: Increased intestinal aryl hydrocarbon receptor expression and pathway sensitivity in Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

P. Harrow1,2*, N. McCarthy1, A. Stagg1, J. Lindsay1,2

Created: Thursday, 21 February 2019, 9:14 AM
DOP017: Patterns of anti-TNF use and associated treatment outcomes in inflammatory bowel disease patients: results from an analysis of Dutch health insurance claims data
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bots S.*1, Hoekman D.1,2, Benninga M.2, Ponsioen C.1, Smeets H.3, D'Haens G.1, Löwenberg M.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP018: Baseline ILC1 distribution in blood predicts response to ustekinumab in patients with refractory Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Creyns1*, B. Verstockt2,3, J. Cremer1, M. Ferrante2,3, S. Vermeire2,3, C. Jan1, G. Van Assche2,3, C. Breynaert1

Created: Thursday, 21 February 2019, 9:14 AM
DOP018: Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Travis S.*1, Feagan B.2, Peyrin-Biroulet L.3, Panaccione R.4, Danese S.5, Lazar A.6, Robinson A.7, Thakkar R.7, Pappalardo B.7, Petersson J.7, Bereswill M.6, Chen N.7, Skup M.7

Created: Wednesday, 20 February 2019, 10:36 AM
DOP018: Long-term follow-up after ileorectal anastomosis in ulcerative colitis (UC) identified factors associated with rectal outcome: a multicentre retrospective cohort of 343 patients from the GETAID/GETAID Surgery
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Uzzan*1, J. Cosnes2, N. Oubaya3, A. Amiot4, N. Gault3, J.-M. Gornet5, P. Seksik2, S. Nancey6, E. Cotte7, M. Allez5, D. Laharie8, N. De angelis4, M. Nachury9, A.-L. Pelletier10, V. Abitbol11, M. Fumery12, A. Brouquet13, A. Buisson14, R. Altwegg15, Y. Panis16, X. Treton1

Created: Friday, 22 February 2019, 9:49 AM
DOP019: Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn's disease: a GEMINI 2 post hoc analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Feagan B.G.*1, Sandborn W.J.2, Colombel J.-F.3, O'Byrne S.4, Khalid J.M.5, Brayshaw N.6, Geransar P.7, Rubin D.T.8

Created: Wednesday, 20 February 2019, 10:36 AM
DOP019: Efficacy of autologous haematopoietic stem cell transplantation for refractory Crohns disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. López García1, M. Rovira2, A. Jauregui Amezaga1, P. Marin3, A. Salas1, S. Pinó Donnay1, R. Barastegui1, F. Feu1, J. Elizalde1, F. Fernández-Avilés2, C. Martínez4, G. Gutierrez2, L. Rosiñol2, E. Carreras2, A. Urbano2, M. Lozano3, J. Cid3, M. Suárez-Lledó2, J. Mensa5, J. Rimola6, S. Rodriguez6, M. C. Masamunt1, D. Comas1, A. Ramirez Morros1, M. Gallego1, I. Ordás1, J. Panés1, E. Ricart*1

Created: Friday, 22 February 2019, 9:49 AM
DOP019: Immunomodulators reduce the risk of surgery and hospitalisation in Crohn’s disease in a prospective European population-based inception cohort: the Epi-IBD cohort
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Burisch1*, V. Andersen2,3, S. Čuković-Čavka4, P.L. Lakatos5, R. D'Inca6, F. Magro7,8,9, N. Arebi10, L. Kievit11, I. Kaimakliotis12, D. Valpiani13, K.H. Katsanos14, Z. Vegh5, J.F. Dahlerup15, M. Fumery16, N. Pedersen17, J. Halfvarson18, E. Belousova19, K.R. Nielsen20, S. Turcan21, P. Ellul22, L. Kupcinskas23, P. Oksanen24, D. Duricova25, M. Giannotta26, A. Goldis27, V. Hernandez28, R. Salupere29, S. Odes30, E. Langholz31, P. Munkholm1, Epi-IBD study group

Created: Thursday, 21 February 2019, 9:14 AM
DOP01: A multi-centre study to explore the prevalence of Inflammatory Bowel Disease indicators in patients with moderate- to- severe psoriasis: Baseline results from the EPIC study
Year: 2022
Source: ECCO'22
Authors: Hayee, B.(1);Ghosh, S.(2);Carter, B.(3);Bartlett, S.(4);Powles, E.(4);Millward, R.(4);Watcham, S.(4);Blanthorn-Hazell, S.(4);Crooks, J.(4);Hansell, C.(4);Millar, J.(5);Williams, C.(5);Migas, S.(5);Hajne, J.(5);Warren, R.(6);
Created: Friday, 11 February 2022, 3:52 PM
Last Modified: Friday, 4 March 2022, 1:45 PM by Dietrich Diz Angerer-GTN
DOP01: Efficacy and safety of the IL-6 trans-signalling inhibitor olamkicept: a phase 2 randomized, placebo-controlled trial in moderately to severely active Ulcerative Colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Chen, B.(1);Zhang, S.(1);Wang, B.(2);Chen, H.(3);Li, Y.(4);Cao, Q.(5);Zhong, J.(6);Xie, M.(7);Ran, Z.(8);Tang, T.(9);Yang, M.(10);Guo, T.(10);Xu, B.(10);Cai, Z.(10);Schreiber, S.(11);Chen, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM